Karolina Vilval
General Counsel at SEDANA MEDICAL AB
Karolina Vilval active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SEDANA MEDICAL AB | General Counsel | 2022-07-31 | - |
| Oncopeptides Incentive AB | Director/Board Member | - | - |
Career history of Karolina Vilval
Former positions of Karolina Vilval
| Companies | Position | Start | End |
|---|---|---|---|
| ONCOPEPTIDES AB | General Counsel | 2020-03-01 | 2022-07-31 |
| Gilead Sciences Sweden AB | General Counsel | - | - |
| SWEDISH ORPHAN BIOVITRUM AB | General Counsel | - | - |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | General Counsel | - | - |
Training of Karolina Vilval
| University of Stockholm | Graduate Degree |
Statistics
International
| Sweden | 8 |
Operational
| General Counsel | 5 |
| Graduate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| SEDANA MEDICAL AB | Health Technology |
| Private companies | 3 |
|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Gilead Sciences Sweden AB | |
| Oncopeptides Incentive AB |
- Stock Market
- Insiders
- Karolina Vilval
- Experience
